Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Experts Debate Precedent Value of Latest Ephedra Decision

This article was originally published in The Tan Sheet

Executive Summary

Food and drug law experts tell "The Tan Sheet" they take a more reserved view than Nutraceutical Corp. attorney Jonathan Emord of a federal court decision that Emord says ensures FDA's final rule banning ephedra is not a "precedent for the creation of a supplement-wide risk-benefit adulteration standard.
Advertisement

Related Content

Will Nutraceutical Succeed In Asking Supreme Court To Review Ephedra Ban?
Nutraceutical Renews Ephedra Case In Utah Court; FDA To Respond By Jan. 18
Nutraceutical Renews Ephedra Case In Utah Court; FDA To Respond By Jan. 18
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly

Topics

Advertisement
UsernamePublicRestriction

Register

PS100335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel